A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma.

Trial Profile

A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms TART
  • Most Recent Events

    • 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top